SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()

Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC. The clinical benefit of sorafenib is offset by the acquisition of sorafenib resistance. Understanding of the molecular mechanism of STAT3...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Su, Jung-Chen, Tseng, Ping-Hui, Wu, Szu-Hsien, Hsu, Cheng-Yi, Tai, Wei-Tien, Li, Yong-Shi, Chen, I-Ting, Liu, Chun-Yu, Chen, Kuen-Feng, Shiau, Chung-Wai
Format: Artigo
Sprog:Inglês
Udgivet: Neoplasia Press 2014
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4198826/
https://ncbi.nlm.nih.gov/pubmed/25047655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2014.06.005
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker